vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $183.1M, roughly 1.4× Amphastar Pharmaceuticals, Inc.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs -1.8%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $24.6M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
AMPH vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $253.4M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 28.7% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 62.7% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $253.4M | ||
| Q3 25 | $191.8M | $244.7M | ||
| Q2 25 | $174.4M | $203.3M | ||
| Q1 25 | $170.5M | $174.6M | ||
| Q4 24 | $186.5M | $155.8M | ||
| Q3 24 | $191.2M | $148.5M | ||
| Q2 24 | $182.4M | $131.1M | ||
| Q1 24 | $171.8M | $118.5M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $51.5M | ||
| Q2 25 | $31.0M | $46.5M | ||
| Q1 25 | $25.3M | $42.9M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $30.5M | ||
| Q2 24 | $37.9M | $25.7M | ||
| Q1 24 | $43.2M | $26.4M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 28.7% | ||
| Q3 25 | 13.2% | 27.4% | ||
| Q2 25 | 24.2% | 29.5% | ||
| Q1 25 | 21.9% | 30.8% | ||
| Q4 24 | 24.2% | 28.9% | ||
| Q3 24 | 29.8% | 25.9% | ||
| Q2 24 | 30.3% | 25.5% | ||
| Q1 24 | 27.9% | 29.0% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 21.0% | ||
| Q2 25 | 17.8% | 22.9% | ||
| Q1 25 | 14.8% | 24.6% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 20.5% | ||
| Q2 24 | 20.8% | 19.6% | ||
| Q1 24 | 25.1% | 22.3% |
| Q4 25 | $0.51 | $2.05 | ||
| Q3 25 | $0.37 | $1.87 | ||
| Q2 25 | $0.64 | $1.68 | ||
| Q1 25 | $0.51 | $1.57 | ||
| Q4 24 | $0.74 | $1.29 | ||
| Q3 24 | $0.78 | $1.15 | ||
| Q2 24 | $0.73 | $1.00 | ||
| Q1 24 | $0.81 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $106.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $942.7M |
| Total Assets | $1.6B | $3.1B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $106.9M | ||
| Q3 25 | $276.2M | $111.7M | ||
| Q2 25 | $231.8M | $81.3M | ||
| Q1 25 | $236.9M | $119.3M | ||
| Q4 24 | $221.6M | $80.4M | ||
| Q3 24 | $250.5M | $86.5M | ||
| Q2 24 | $217.8M | $47.8M | ||
| Q1 24 | $289.6M | $61.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $942.7M | ||
| Q3 25 | $776.7M | $878.1M | ||
| Q2 25 | $757.5M | $847.2M | ||
| Q1 25 | $751.3M | $790.4M | ||
| Q4 24 | $732.3M | $729.0M | ||
| Q3 24 | $727.7M | $703.3M | ||
| Q2 24 | $713.3M | $532.6M | ||
| Q1 24 | $672.4M | $501.7M |
| Q4 25 | $1.6B | $3.1B | ||
| Q3 25 | $1.7B | $2.9B | ||
| Q2 25 | $1.6B | $2.8B | ||
| Q1 25 | $1.6B | $2.4B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.5B | $2.3B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.6B | $1.9B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $409.1M |
| Free Cash FlowOCF − Capex | $24.6M | $409.0M |
| FCF MarginFCF / Revenue | 13.4% | 161.4% |
| Capex IntensityCapex / Revenue | 4.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $409.1M | ||
| Q3 25 | $52.6M | $83.6M | ||
| Q2 25 | $35.6M | $120.9M | ||
| Q1 25 | $35.1M | $87.2M | ||
| Q4 24 | $29.0M | $261.2M | ||
| Q3 24 | $60.0M | $100.3M | ||
| Q2 24 | $69.1M | $55.1M | ||
| Q1 24 | $55.3M | $33.1M |
| Q4 25 | $24.6M | $409.0M | ||
| Q3 25 | $47.2M | $83.6M | ||
| Q2 25 | $25.0M | $120.8M | ||
| Q1 25 | $24.4M | $87.1M | ||
| Q4 24 | $16.6M | $260.9M | ||
| Q3 24 | $46.2M | $100.1M | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 161.4% | ||
| Q3 25 | 24.6% | 34.2% | ||
| Q2 25 | 14.3% | 59.4% | ||
| Q1 25 | 14.3% | 49.9% | ||
| Q4 24 | 8.9% | 167.5% | ||
| Q3 24 | 24.1% | 67.4% | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.63× | ||
| Q2 25 | 1.15× | 2.60× | ||
| Q1 25 | 1.39× | 2.03× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 3.29× | ||
| Q2 24 | 1.82× | 2.14× | ||
| Q1 24 | 1.28× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PLMR
Segment breakdown not available.
